Global Human Insulin Market Size study, By Product Type (Insulin Analogs and Biosimilars (Rapid-acting, Long-acting, Premixed), Human Insulin Biologics (Short-acting, Intermediate-acting, Premixed)), By Type (Insulin Analogs and Biosimilars (Long-Acting Biosimilars, Rapid-Acting Biosimilars, Premixed Biosimilars), HI Biologics (Short-Acting Biologics, Intermediate-Acting Biologics, Premixed Biologics)), By Delivery Devices (Pens, Pen Needles, Syringes), By Brand (Insulin Analogs and Biosimilars (Lantus, NovoRapid/Novolog, Humalog, Other Brands), Human Insulin Biologics (Actrapid, Insulatard, and Mixtard, Humulin, Insuman)), By Application (Type I Diabetes, Type II Diabetes), and Regional Forecasts 2022-2028
- BIZ4952928
- 200 Pages
- April 2022
- Healthcare
Human insulin works by assisting move sugar from the blood into further body tissues where it is devoured for energy and it also prevents the liver from producing more sugar. Human insulin is manufactured through genetic engineering by injecting insulin-producing genes into bacteria. This technique has reduced the cost of manufacturing by some manifolds. The growing number of diabetic patients, increasing demand for the HI analogs, technological developments in HI delivery devices, presence of favorable medical reimbursement scenarios in various regions are the primary factors that are augmenting the market demand around the world. For instance, according to the International Diabetic Federation (IDF), in 2019, there were nearly 463 million adults aged between 20-79 years were suffering from diabetes. Also, the amount is anticipated to reach around 700 million by 2045. Consequentially, the growing prevalence of diabetes is fostering the demand for human insulin, which, in turn, accelerates market growth in the near future. However, high product manufacturing costs and stringent regulatory requirements for product approval impede the growth of the market over the forecast period of 2022-2028. Also, the development of the emerging markets and expected patent expiry of key HI drugs is anticipated to act as a catalyzing factor for the market demand during the forecast period.
The key regions considered for the global Human Insulin market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the growing responsiveness to benefits offered by human insulin in diabetes treatment and the presence of major market players in the region. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as growing incidences of diabetes, as well as escalating population, would create lucrative growth prospects for the Human Insulin market across the Asia-Pacific region.
Major market players included in this report are:
Sanofi S.A.
Novo Nordisk A/S
Eli Lilly and Company
Biocon Ltd.
Julphar
Ypsomed AG
Becton, Dickinson and Company
Wockhardt Ltd.
B. Braun Meselgen AG
Biodel Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product Type:
Insulin Analogs and Biosimilars
Rapid-acting
Long-acting
Premixed
Human Insulin Biologics
Short-acting
Intermediate-acting
Premixed
By Type:
Insulin Analogs and Biosimilars
Long-Acting Biosimilars
Rapid-Acting Biosimilars
Premixed Biosimilars
HI Biologics
Short-Acting Biologics
Intermediate-Acting Biologics
Premixed Biologics
By Delivery Devices:
Pens
Pen Needles
Syringes
By Brand:
Insulin Analogs and Biosimilars
Lantus
NovoRapid/Novolog
Humalog
Other Brands
Human Insulin Biologics
Actrapid, Insulatard, and Mixtard
Humulin
Insuman
By Application:
Type I Diabetes
Type II Diabetes
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Human Insulin Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
1.2.1. Global Human Insulin Market, by Region, 2020-2028 (USD Billion)
1.2.2. Global Human Insulin Market, by Product Type, 2020-2028 (USD Billion)
1.2.3. Global Human Insulin Market, by Type, 2020-2028 (USD Billion)
1.2.4. Global Human Insulin Market, by Delivery Devices, 2020-2028 (USD Billion)
1.2.5. Global Human Insulin Market, by Brand, 2020-2028 (USD Billion)
1.2.6. Global Human Insulin Market, by Application, 2020-2028 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Human Insulin Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Human Insulin Market Dynamics
3.1. Human Insulin Market Impact Analysis (2020-2028)
3.1.1. Market Drivers
3.1.1.1. Increasing incidences of diabetic patients
3.1.1.2. Technological advancements in HI delivery devices
3.1.2. Market Challenges
3.1.2.1. High product manufacturing costs
3.1.2.2. Stringent regulatory requirements for product approval
3.1.3. Market Opportunities
3.1.3.1. Development of the emerging Markets
3.1.3.2. Expected patent expiry of key HI drugs
Chapter 4. Global Human Insulin Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Human Insulin Market, by Product Type
6.1. Market Snapshot
6.2. Global Human Insulin Market by Product Type, Performance - Potential Analysis
6.3. Global Human Insulin Market Estimates & Forecasts by Product Type 2018-2028 (USD Billion)
6.4. Human Insulin Market, Sub Segment Analysis
6.4.1. Insulin Analogs and Biosimilars
6.4.1.1. Rapid-acting
6.4.1.2. Long-acting
6.4.1.3. Premixed
6.4.2. Human Insulin Biologics
6.4.2.1. Short-acting
6.4.2.2. Intermediate-acting
6.4.2.3. Premixed
Chapter 7. Global Human Insulin Market, by Type
7.1. Market Snapshot
7.2. Global Human Insulin Market by Type, Performance - Potential Analysis
7.3. Global Human Insulin Market Estimates & Forecasts by Type 2018-2028 (USD Billion)
7.4. Human Insulin Market, Sub Segment Analysis
7.4.1. Insulin Analogs and Biosimilars
7.4.1.1. Long-Acting Biosimilars
7.4.1.2. Rapid-Acting Biosimilars
7.4.1.3. Premixed Biosimilars
7.4.2. HI Biologics
7.4.2.1. Short-Acting Biologics
7.4.2.2. Intermediate-Acting Biologics
7.4.2.3. Premixed Biologics
Chapter 8. Global Human Insulin Market, by Delivery Devices
8.1. Market Snapshot
8.2. Global Human Insulin Market by Delivery Devices, Performance - Potential Analysis
8.3. Global Human Insulin Market Estimates & Forecasts by Delivery Devices 2018-2028 (USD Billion)
8.4. Human Insulin Market, Sub Segment Analysis
8.4.1. Pens
8.4.2. Pen Needles
8.4.3. Syringes
Chapter 9. Global Human Insulin Market, by Brand
9.1. Market Snapshot
9.2. Global Human Insulin Market by Brand, Performance - Potential Analysis
9.3. Global Human Insulin Market Estimates & Forecasts by Brand 2018-2028 (USD Billion)
9.4. Human Insulin Market, Sub Segment Analysis
9.4.1. Insulin Analogs and Biosimilars
9.4.1.1. Lantus
9.4.1.2. NovoRapid/Novolog
9.4.1.3. Humalog
9.4.1.4. Other Brands
9.4.2. Human Insulin Biologics
9.4.2.1. Actrapid, Insulatard, and Mixtard
9.4.2.2. Humulin
9.4.2.3. Insuman
Chapter 10. Global Human Insulin Market, by Application
10.1. Market Snapshot
10.2. Global Human Insulin Market by Application, Performance - Potential Analysis
10.3. Global Human Insulin Market Estimates & Forecasts by Application 2018-2028 (USD Billion)
10.4. Human Insulin Market, Sub Segment Analysis
10.4.1. Type I Diabetes
10.4.2. Type II Diabetes
Chapter 11. Global Human Insulin Market, Regional Analysis
11.1. Human Insulin Market, Regional Market Snapshot
11.2. North America Human Insulin Market
11.2.1. U.S. Human Insulin Market
11.2.1.1. Product Type estimates & forecasts, 2018-2028
11.2.1.2. Type estimates & forecasts, 2018-2028
11.2.1.3. Delivery Devices estimates & forecasts, 2018-2028
11.2.1.4. Brand estimates & forecasts, 2018-2028
11.2.1.5. Application estimates & forecasts, 2018-2028
11.2.2. Canada Human Insulin Market
11.3. Europe Human Insulin Market Snapshot
11.3.1. U.K. Human Insulin Market
11.3.2. Germany Human Insulin Market
11.3.3. France Human Insulin Market
11.3.4. Spain Human Insulin Market
11.3.5. Italy Human Insulin Market
11.3.6. Rest of Europe Human Insulin Market
11.4. Asia-Pacific Human Insulin Market Snapshot
11.4.1. China Human Insulin Market
11.4.2. India Human Insulin Market
11.4.3. Japan Human Insulin Market
11.4.4. Australia Human Insulin Market
11.4.5. South Korea Human Insulin Market
11.4.6. Rest of Asia Pacific Human Insulin Market
11.5. Latin America Human Insulin Market Snapshot
11.5.1. Brazil Human Insulin Market
11.5.2. Mexico Human Insulin Market
11.6. Rest of The World Human Insulin Market
Chapter 12. Competitive Intelligence
12.1. Top Market Strategies
12.2. Company Profiles
12.2.1. Sanofi S.A.
12.2.1.1. Key Information
12.2.1.2. Overview
12.2.1.3. Financial (Subject to Data Availability)
12.2.1.4. Product Type Summary
12.2.1.5. Recent Developments
12.2.2. Novo Nordisk A/S
12.2.3. Eli Lilly and Company
12.2.4. Biocon Ltd.
12.2.5. Julphar
12.2.6. Ypsomed AG
12.2.7. Becton, Dickinson and Company
12.2.8. Wockhardt Ltd.
12.2.9. B. Braun Meselgen AG
12.2.10. Biodel Inc.
Chapter 13. Research Process
13.1. Research Process
13.1.1. Data Mining
13.1.2. Analysis
13.1.3. Market Estimation
13.1.4. Validation
13.1.5. Publishing
13.2. Research Attributes
13.3. Research Assumption
TABLE 1. Global Human Insulin Market, report scope
TABLE 2. Global Human Insulin Market estimates & forecasts by Region 2018-2028 (USD Billion)
TABLE 3. Global Human Insulin Market estimates & forecasts by Product Type 2018-2028 (USD Billion)
TABLE 4. Global Human Insulin Market estimates & forecasts by Type 2018-2028 (USD Billion)
TABLE 5. Global Human Insulin Market estimates & forecasts by Delivery Devices 2018-2028 (USD Billion)
TABLE 6. Global Human Insulin Market estimates & forecasts by Brand 2018-2028 (USD Billion)
TABLE 7. Global Human Insulin Market estimates & forecasts by Application 2018-2028 (USD Billion)
TABLE 8. Global Human Insulin Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 9. Global Human Insulin Market by region, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 10. Global Human Insulin Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 11. Global Human Insulin Market by region, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 12. Global Human Insulin Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 13. Global Human Insulin Market by region, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 14. Global Human Insulin Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 15. Global Human Insulin Market by region, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 16. Global Human Insulin Market by segment, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 17. Global Human Insulin Market by region, estimates & forecasts, 2018-2028 (USD Billion)
TABLE 18. U.S. Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 19. U.S. Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 20. U.S. Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 21. Canada Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 22. Canada Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 23. Canada Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 24. UK Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 25. UK Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 26. UK Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 27. Germany Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 28. Germany Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 29. Germany Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 30. RoE Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 31. RoE Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 32. RoE Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 33. China Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 34. China Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 35. China Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 36. India Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 37. India Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 38. India Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 39. Japan Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 40. Japan Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 41. Japan Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 42. RoAPAC Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 43. RoAPAC Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 44. RoAPAC Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 45. Brazil Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 46. Brazil Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 47. Brazil Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 48. Mexico Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 49. Mexico Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 50. Mexico Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 51. RoLA Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 52. RoLA Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 53. RoLA Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 54. Row Human Insulin Market estimates & forecasts, 2018-2028 (USD Billion)
TABLE 55. Row Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 56. Row Human Insulin Market estimates & forecasts by segment 2018-2028 (USD Billion)
TABLE 57. List of secondary sources, used in the study of global Human Insulin Market
TABLE 58. List of primary sources, used in the study of global Human Insulin Market
TABLE 59. Years considered for the study
TABLE 60. Exchange rates considered
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
